{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:59:07Z","timestamp":1787795947545,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejpb.2021.08.019","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:41:23Z","timestamp":1630449683000},"page":"110-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics\/pharmacodynamics model"],"prefix":"10.1016","volume":"168","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Giragossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejpb.2021.08.019_b0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/14712598.8.8.1151","article-title":"Approved monoclonal antibodies for cancer therapy","volume":"8","author":"Boyiadzis","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejpb.2021.08.019_b0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2013.08.298","article-title":"Targeting tumors with nanobodies for cancer imaging and therapy","volume":"172","author":"Oliveira","year":"2013","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.ejpb.2021.08.019_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tibtech.2007.05.001","article-title":"Engineering antibodies for clinical applications","volume":"25","author":"Jain","year":"2007","journal-title":"Trends Biotechnol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.08.019_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2009.08.003","article-title":"Differential tumor-targeting abilities of three single-domain antibody formats","volume":"289","author":"Bell","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2021.08.019_b0025","doi-asserted-by":"crossref","first-page":"118791","DOI":"10.1016\/j.lfs.2020.118791","article-title":"Recent developments in antibody derivatives against colorectal cancer. A review","volume":"265","author":"Ghani","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2021.08.019_b0030","first-page":"188","article-title":"Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts","volume":"48","author":"Sands","year":"1988","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejpb.2021.08.019_b0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/1535-7163.MCT-13-0748","article-title":"Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy","volume":"13","author":"Shin","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2021.08.019_b0040","first-page":"5144","article-title":"Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier","volume":"52","author":"Juweid","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0045","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejpb.2021.08.019_b0050","doi-asserted-by":"crossref","first-page":"e1004142","DOI":"10.1371\/journal.pcbi.1004142","article-title":"Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy","volume":"11","author":"Fu","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0055","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy","volume":"18","author":"Cilliers","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2021.08.019_b0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.08.019_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00165","article-title":"Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid","volume":"5","author":"Baronzio","year":"2015","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.08.019_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","article-title":"Target-mediated drug disposition and dynamics","volume":"72","author":"Mager","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"6","key":"10.1016\/j.ejpb.2021.08.019_b0080","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0085","first-page":"4776","article-title":"An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a \u201cbinding site barrier\u201d","volume":"51","author":"van Osdol","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0090","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/(SICI)1097-0290(19990305)62:5<562::AID-BIT8>3.0.CO;2-4","article-title":"Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids","volume":"62","author":"Wenning","year":"1999","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejpb.2021.08.019_b0095","first-page":"1552","article-title":"A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin","volume":"34","author":"van Osdol","year":"1993","journal-title":"J. Nucl. Med. Offic. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.ejpb.2021.08.019_b0100","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J. Nucl. Med. Offic. Publ. Soc. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2021.08.019_b0105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3495(95)79956-8","article-title":"Effects of cellular pharmacology on drug distribution in tissues","volume":"69","author":"Rippley","year":"1995","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2021.08.019_b0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jtbi.2012.08.034","article-title":"A mechanistic compartmental model for total antibody uptake in tumors","volume":"314","author":"Thurber","year":"2012","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0022-5193(72)90058-6","article-title":"Capillary-tissue exchange kinetics: an analysis of the Krogh cylinder model","volume":"34","author":"Levitt","year":"1972","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0120","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0125","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1073\/pnas.92.19.8999","article-title":"Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier","volume":"92","author":"Saga","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2021.08.019_b0130","first-page":"3119","article-title":"Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies","volume":"51","author":"Yuan","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0135","first-page":"1517","article-title":"Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice","volume":"54","author":"Baxter","year":"1994","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejpb.2021.08.019_b0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"2","key":"10.1016\/j.ejpb.2021.08.019_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1054\/mehy.2001.1288","article-title":"Model of interstitial pressure as a result of cyclical changes in the capillary wall fluid transport","volume":"57","author":"Kurbel","year":"2001","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejpb.2021.08.019_b0155","first-page":"4478","article-title":"Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy","volume":"50","author":"Boucher","year":"1990","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.ejpb.2021.08.019_b0160","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1158\/1078-0432.CCR-04-2332","article-title":"Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors","volume":"11","author":"Flessner","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejpb.2021.08.019_b0165","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","article-title":"Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice","volume":"34","author":"Garg","year":"2007","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.ejpb.2021.08.019_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00720","article-title":"Tumor-associated lymphatic vessel features and immunomodulatory functions","volume":"10","author":"Garnier","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0175","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","article-title":"Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer","volume":"92","author":"Wiig","year":"2012","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2021.08.019_b0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2008.07.006","article-title":"The biological properties of cetuximab","volume":"68","author":"Vincenzi","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.ejpb.2021.08.019_b0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejpb.2021.08.019_b0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-005-1022-3","article-title":"Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft","volume":"56","author":"Luo","year":"2005","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0195","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3892\/ijo_00000551","article-title":"Quantification of internalization of EGFR-binding Affibody molecules: methodological aspects","volume":"36","author":"Gostring","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0200","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1593\/neo.07721","article-title":"Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody","volume":"9","author":"Perera","year":"2007","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.ejpb.2021.08.019_b0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","article-title":"ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope","volume":"15","author":"Phillips","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ejpb.2021.08.019_b0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2021.08.019_b0215","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10616-017-0125-0","article-title":"Cytotoxicity and apoptotic cell death induced by Vitis vinifera peel and seed extracts in A431 skin cancer cells","volume":"70","author":"Nirmala","year":"2018","journal-title":"Cytotechnology"},{"key":"10.1016\/j.ejpb.2021.08.019_b0220","doi-asserted-by":"crossref","first-page":"e110003","DOI":"10.1371\/journal.pone.0110003","article-title":"Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest","volume":"9","author":"Ahamad","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2021.08.019_b0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejpb.2021.08.019_b0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2008.07.002","article-title":"Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs","volume":"14","author":"Gascoigne","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejpb.2021.08.019_b0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2021.08.019_b0240","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/msb.2013.47","article-title":"Protein synthesis rate is the predominant regulator of protein expression during differentiation","volume":"9","author":"Kristensen","year":"2013","journal-title":"Mol. Syst. Biol."},{"issue":"6","key":"10.1016\/j.ejpb.2021.08.019_b0245","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.bjc.6602470","article-title":"Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR","volume":"92","author":"Panousis","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2021.08.019_b0250","first-page":"1288","article-title":"Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention","volume":"63","author":"Graff","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HP.S133231","article-title":"A review of the development of tumor vasculature and its effects on the tumor microenvironment","volume":"5","author":"Forster","year":"2017","journal-title":"Hypoxia (Auckl)."},{"issue":"12","key":"10.1016\/j.ejpb.2021.08.019_b0260","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ejpb.2021.08.019_b0310","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-16-0383","article-title":"EGFR downregulation after anti-EGFR therapy predicts the antitumor effect in colorectal cancer","volume":"15","author":"Okada","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.019_b0315","unstructured":"C. Tsai, C. Giragossian, S. Hansel, Revisiting Contribution of Convection and Diffusion to Antibody Transport from Tumor Apiculture to Interstitium, Poster Presented at: The Ninth American Conference on Pharmacometrics; 2018 OCT 7-10; San Diego, CA, n.d."},{"key":"10.1016\/j.ejpb.2021.08.019_b0320","doi-asserted-by":"crossref","first-page":"798936","DOI":"10.1155\/2015\/798936","article-title":"Effects of activating mutations on EGFR cellular protein turnover and amino acid recycling determined using SILAC mass spectrometry","volume":"2015","author":"Greig","year":"2015","journal-title":"Int. J. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.08.019_b0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"10","key":"10.1016\/j.ejpb.2021.08.019_b0330","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2021.08.019_b0335","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11095-014-1462-8","article-title":"Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals","volume":"32","author":"Vainshtein","year":"2015","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:44:29Z","timestamp":1760546669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":57,"alternative-id":["S0939641121002319"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.08.019","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics\/pharmacodynamics model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}